Hepatitis C: A clinical review

Oral Diseases

Volumn 14, Issue 1, 2008, Pages 10-14

  Modi, A A ^a   Liang, T J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Genotype; Natural history; Peginterferon; Ribavirin; Therapy

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ANXIETY DISORDER; ASCITES; AUTOIMMUNE THYROIDITIS; CHOLELITHIASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DUPUYTREN CONTRACTURE; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GOUT; GYNECOMASTIA; HAIR LOSS; HEADACHE; HEALTH CARE COST; HEARING DISORDER; HEART DISEASE; HEART INFARCTION; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATOSPLENOMEGALY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTERSTITIAL NEPHRITIS; IRON OVERLOAD; IRRITABILITY; LEUKOPENIA; LIVER INJURY; LYMPHOCYTOPENIA; MONOTHERAPY; MUSCLE ATROPHY; MYALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; PAROTID ENLARGEMENT; PRIORITY JOURNAL; PRURITUS; RETINA DISEASE; REVIEW; SEIZURE; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; SPIDER VEIN; TEMPORALIS MUSCLE; TERATOGENICITY; TESTIS ATROPHY; THROMBOCYTOPENIA; VISUAL DISORDER;

ANTIVIRAL AGENTS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS;

EID: 37349020028     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2007.01419.x     Document Type: Review

References (33)

1. Alberti A, Boccato S, Vario A, Benvegnu L (2002). Therapy of acute hepatitis C. Hepatology 36 (5 Suppl. 1 S195 S200.
2. Alter MJ, Kruszon-Moran D, Nainan OV et al (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341: 556 562.
3. Bacon BR (2002). Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36 (5 Suppl. 1 S179 S184.
4. Davis GL (2002). Monitoring of viral levels during therapy of hepatitis C. Hepatology 36 (5 Suppl. 1 S145 S151.
5. Di Bisceglie AM (2000). Natural history of hepatitis C: its impact on clinical management. Hepatology 31: 1014 1018.
6. Di Bisceglie AM, Hoofnagle JH (2002). Optimal therapy of hepatitis C. Hepatology 36 (5 Suppl. 1 S121 S127.
7. Dienstag JL, McHutchison JG (2006). American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130: 231 264 quiz 14-17.
8. El-Zayadi AR, Attia M, Barakat EM et al (2005). Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 100: 2447 2452.
9. Fattovich G, Giustina G, Degos F et al (1997). Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463 472.
10. Fattovich G, Stroffolini T, Zagni I, Donato F (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (5 Suppl. 1 S35 S50.
11. Feld JJ, Hoofnagle JH (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967 972.
12. Fried MW (2002). Side effects of therapy of hepatitis C and their management. Hepatology 36 (5 Suppl. 1 S237 S244.
13. Fried MW, Shiffman ML, Reddy KR et al (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975 982.
14. Gerlach JT, Diepolder HM, Zachoval R et al (2003). Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125: 80 88.
15. Hadziyannis SJ, Sette H Jr., Morgan TR et al (2004). Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346 355.
16. Hofer H, Watkins-Riedel T, Janata O et al (2003). Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 37: 60 64.
17. Hoofnagle JH (2002). Course and outcome of hepatitis C. Hepatology 36 (5 Suppl. 1 S21 S29.
18. Hoofnagle JH, Seeff LB (2006). Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355: 2444 2451.
19. Hu KQ, Tong MJ (1999). The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29: 1311 1316.
20. Kamal SM, Ismail A, Graham CS et al (2004). Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 39: 1721 1731.
21. Kamal SM, Fouly AE, Kamel RR et al (2006). Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130: 632 638.
22. Kleiner DE (2005). The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 25: 52 64.
23. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH (2000). Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132: 296 305.
24. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R (2005). High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41: 275 279.
25. Lindenbach BD, Rice CM (2005). Unravelling hepatitis C virus replication from genome to function. Nature 436: 933 938.
26. Manns MP, McHutchison JG, Gordon SC et al (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958 965.
27. McHutchison JG, Manns M, Patel K et al (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061 1069.
28. Pawlotsky JM (2007). Treatment of hepatitis C: don't put all your eggs in one basket! Gastroenterology 132: 1611 1615.
29. Shah BB, Wong JB (2006). The economics of hepatitis C virus. Clin Liver Dis 10: 717 734.
30. Strader DB, Wright T, Thomas DL, Seeff LB (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147 1171.
31. Thomas DL, Seeff LB (2005). Natural history of hepatitis C. Clin Liver Dis 9: 383 398, vi.
32. Wasley A, Alter MJ (2000). Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20: 1 16.
33. Wiegand J, Buggisch P, Boecher W et al (2006). Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43: 250 256.